NCT00500058 is a Phase 1 clinical trial of SB-485232 in Lymphoma, Non-Hodgkin, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00500058?

NCT00500058 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00500058?

Interventions in NCT00500058: SB-485232, Rituximab.

What condition does NCT00500058 study?

NCT00500058 studies Lymphoma, Non-Hodgkin.

Is NCT00500058 still recruiting?

NCT00500058 is currently completed. Last updated 26 July 2017.

Last reviewed 2017-07-26 · How we verify

NCT00500058

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

Completed Phase 1 Last updated 26 July 2017

What this trial tests

Phase 1 trial testing SB-485232 in Lymphoma, Non-Hodgkin in 24 participants. Completed in 4 March 2010.

Timeline

31 July 2007

Primary endpoint
4 March 2010

4 March 2010

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	31 July 2007
Primary completion	4 March 2010
Estimated completion	4 March 2010
Sites	2 locations across United States

Drugs / interventions tested

SB-485232 — full drug profile →
Rituximab — full drug profile →

Conditions studied

Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, any sex, with Lymphoma, Non-Hodgkin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL). This study will use a standard treatment regimen of Rituximab in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration.
Doyle SL, Ozaki E, Brennan K, Humphries MM, et al · · 2014 · cited 79× · PMID 24695684 · DOI 10.1126/scitranslmed.3007616
Involvement of inflammasomes in tumor microenvironment and tumor therapies.
Zhang Z, Li X, Wang Y, Wei Y, et al · · 2023 · cited 55× · PMID 36932407 · DOI 10.1186/s13045-023-01407-7
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma.
Robertson MJ, Kline J, Struemper H, Koch KM, et al · · 2013 · cited 32× · PMID 23799412 · DOI 10.1097/cji.0b013e31829d7e2e
Co-delivery of IL-12/IL-15/IL-18 engineered DC vaccines with anti-IL-10R and nanoconjugated methotrexate in melanoma.
Węgierek-Ciura K, Szczygieł A, Rudawska A, Mierzejewska J, et al · · 2026 · PMID 41846923 · DOI 10.3389/fimmu.2026.1773836
Inflammasomes in lymphocytes as therapeutic targets.
Albakova Z. · · 2025 · PMID 40054124 · DOI 10.1016/j.tranon.2025.102342

Verify or expand the search:

Other trials of SB-485232

Trials testing the same drug.

NCT00107718 — Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma · Phase 2 · completed

Other recruiting trials for Lymphoma, Non-Hodgkin

Currently open trials in the same condition.

NCT07308132 — A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · Phase 1 · recruiting
NCT06923397 — Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemother · NA · recruiting
NCT06660563 — A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell No · Phase 1 · active not recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06470438 — A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma · Phase 1 · active not recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00500058 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 26 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00500058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing